Actelion Grows Its PAH Franchise With Uptravi Approval
Broad label for oral product could help Actelion weather the loss of Tracleer to generic competition.
You may also be interested in...
The Swiss biotech’s top-selling product Tracleer still accounts for 75% of its sales but Actelion has a strategy that includes launching new PAH therapies and developing a specialty pharma pipeline to cope with the upcoming loss of patent protection.
Amgen exec calls for more informal agency feedback and alignment between review divisions in understanding design methodologies.